Medical/Pharmaceuticals

Infosys Chosen by NHSBSA to Deliver a New Workforce Management Solution for the NHS in England and Wales

Next-Generation solution supports the NHS 10-year Health Plan and the mission to create a workforce that is fit for the future LONDON and BENGALURU, India, Oct. 14, 2025 /PRNewswire/ -- Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next-generation di...

2025-10-14 18:02 977

Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration

- Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a Phase III randomized, double-blind, placebo-controlled, multicenter clinical trial. HONG KONG, Oct. 14, 2025...

2025-10-14 18:00 1251

Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded

MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides an update on its commercial and operational performance for the quarter ended30 September 2025 (Q3 2025). All figures are in USD unless stated otherwi...

2025-10-14 14:59 1364

Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) Presented Preclinical Data on GNTbm-TKI, a Novel Multi-tyrosine Kinase Inhibitor with Potent Immune Activation, at the 2025 ESMO Annual Meeting

TAIPEI, Oct. 14, 2025 /PRNewswire/ -- GNTbm (stock code: 7427, Taiwan) announced the preclinical data on GNTbm-TKI, a novel multi-receptor tyrosine kinase inhibitor for cancer immunotherapy. GNTbm-TKI will be presented as posters at the 2025European Society for Medical Oncology (ESMO) Annual Meet...

2025-10-14 14:26 899

2025 ACR Abstract Released! Exciting Data from Telitacicept's Phase III Clinical Study in Sjögren's Syndrome in China

* In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (European League Against Rheumatism) Sjögren's Syndrome Disease Activity Index] compared to placebo. * Teli...

2025-10-14 13:44 487

Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14

SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the first patient has been enro...

2025-10-14 12:13 1109

Natural Field Drives Breakthroughs in Co-loading Liposome Technology, Accelerating Upgrading of Raw Materials for Cardiovascular and Gut Health

XIAN, China, Oct. 13, 2025 /PRNewswire/ -- Natural Field has achieved new continuous research breakthroughs in co-loading liposome technology, with remarkable progress particularly in the development of co-loading Coenzyme Q10 (CoQ10) liposome and co-loading curcumin liposome raw materials. This ...

2025-10-13 23:00 1124

Visionary Holdings (Nasdaq: GV) Secures Global License for Breakthrough Stem Cell Technology Aimed at Diabetes Remission and Potential Complete Cure in a USD 150 Billion Global Market

TORONTO, Oct. 13, 2025 /PRNewswire/ -- Visionary Holdings Inc. ("GV" or the "Company"), a technology-driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced that its wholly owned subsidiary,Visionary Holdings (Asia) Limited, has entered into a Global Product and Technology ...

2025-10-13 21:40 1515

iRegene Therapeutics announced promising NouvNeu001 Phase I clinical data

CHENGDU, China, Oct. 13, 2025 /PRNewswire/ -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company") is recognized as a biotechnology company pioneering chemically induced allogeneic cell therapy. iRegene's lead product, NouvNeu001, is the 1st iPSC therapy to receive IND approval from both t...

2025-10-13 21:00 944

NEXTBIOMEDICAL Announces First Patient Enrolled in U.S. FDA Pivotal Trial of Nexsphere-F™ for Knee Osteoarthritis Pain

* RESORB Study Marks Major Step Toward U.S. Regulatory Approval and Global Commercialization SEOUL, South Korea, Oct. 13, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based inSouth Korea, today announced the enrollment of the first patient...

2025-10-13 21:00 1055

Complete Genomics announces Gene by Gene as its newest sequencing service provider at ASHG

BOSTON, Oct. 13, 2025 /PRNewswire/ -- Complete Genomics , a leading innovator in genomic sequencing, today announced at the American Society of Human Genetics Annual Meeting that it has addedHouston-based Gene by Gene,  a leading ge...

2025-10-13 21:00 1056

Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics

Headlines: * Xevo™ CDMS facilitates direct, accurate mass detection for the largest, most heterogeneous biomolecules.1 * Enables accurate analysis of protein complexes, nucleic acids, and gene delivery vehicles, including distinguishing between empty, partial, full, and overfull viral vector...

2025-10-13 20:36 1272

Thousand Oaks Biologics Shanghai ADC Site receives EU QP Declaration

SHANGHAI, Oct. 13, 2025 /PRNewswire/ -- Thousand Oaks Biologics' antibody-drug conjugate (ADC) manufacturing site successfully passed an audit conducted by a European Union Qualified Person (QP) and formally received a QP Declaration. This milestone certifies that the company's quality management...

2025-10-13 20:00 868

Chiron Medical Launches "Early Check, Early Hope" Campaign, Embracing Pink for Breast Cancer Awareness

HONG KONG, Oct. 13, 2025 /PRNewswire/ -- According to government statistics[1], breast cancer ranks as the third leading cause of cancer deaths among women in Hong Kong, with an average of one in every 14 women likely to be diagnosed with the disease in their lifetime. The medical community widely...

2025-10-13 19:46 1000

ReviR Therapeutics Receives Orphan Drug Designation from FDA for RTX-117 to Treat Charcot-Marie-Tooth Disease

BRISBANE, Calif. , Oct. 13, 2025 /PRNewswire/ -- ReviR Therapeutics, a biotech company focused on developing novel treatments for neurogenetic diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for RTX-117, its lead investigational...

2025-10-13 18:00 938

LTS expands its CDMO capabilities with the acquisition of Renaissance Lakewood

ANDERNACH, Germany, Oct. 13, 2025 /PRNewswire/ -- LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company today announces the acquisition of Renaissance Lakewood, LLC ("Renaissance"), a US-based contract development and manufacturing organization (CDMO) specializing i...

2025-10-13 18:00 1102

AnnJi Showcases Clinical Breakthrough of AJ201 at WMS 2025

TAIPEI, Oct. 13, 2025 /PRNewswire/ -- AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) announced that the Phase 2a clinical result of AJ201 for spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's disease) was selected as one of the seven Late-Breaking Abstracts at the World Muscle...

2025-10-13 16:03 1088

The 138th Canton Fair is Set to Open in Guangzhou on October 15

GUANGZHOU, China, Oct. 13, 2025 /PRNewswire/ -- The 138th China Import and Export Fair (Canton Fair) is set to open inGuangzhou from October 15 to November 4, divided into three phases. The fair will maintain its 24-hour online presence to offer global buyers continuous access to Chinese supplier...

2025-10-13 14:42 1708

Lundbeck's bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies

* Accelerated pathway underscores urgent need for innovative solutions for patients with devastating, childhood-onset epilepsies * Novel 5HT2C mechanism designed to reduce drug-resistant seizures in children and adults living with Developmental Epileptic Encephalopathies (DEEs) and improve qu...

2025-10-13 14:26 988

ISTH marks World Thrombosis Day with urgent global call to action

Thrombosis is the underlying cause of 1 in 4 deaths worldwide each year. The campaign calls for crucial awareness and prevention. CHARLOTTE, N.C., Oct. 13, 2025 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis

2025-10-13 14:00 699
1 ... 24252627282930 ... 645

Week's Top Stories